All Ashley Tuan Articles

NaturalVue Multifocals Prove to be Effective for Astigmatism Correction

January 17, 2025 LAS VEGAS — New research findings from Visioneering Technologies Inc. (VTI) are highlighting another benefit of NaturalVue Multifocal contact...

619

VTI Shares Preliminary Two-Year Data from PROTECT Study

January 17, 2025 LAS VEGAS — Visioneering Technologies Inc. (VTI) has shared the preliminary two-year findings from its ongoing PROTECT (PROgressive Myopia...

825

VTI Shares New Findings from its PROTECT Study of the NaturalVue Multifocal Contact Lens

sponsored content December 16, 2024 Recently discovered findings continue emerging from the PROTECT RCT (PROgressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial) being conducted by Visioneering...

699

VTI’s Chief Medical Officer Dr. Ashley Tuan Shares PROTECT Study Data at IMC

sponsored content October 15, 2024 SANYA, Hainan Island, China – Dr. Ashley Tuan, OD, PhD, the Chief Medical Officer of Visioneering Technologies,...

542

VTI Presents Latest PROTECT Trial Data at Myopia Conferences

October 7, 2024 HAINAN ISLAND, China, and DALLAS, Texas — Visioneering Technologies Inc. (VTI) has presented the latest data from its PROTECT...

1.5K

VTI Shares Latest Data From PROTECT Study at ARVO 2024

May 6, 2024 SEATTLE, Wash. — Visioneering Technologies Inc. has shared the latest data from its PROTECT (PROgressive Myopia Treatment Evaluation for...

Podcasts

New Data and Fitting Experience Revealed for VTI’s NaturalVue Multifocal Contact Lenses

sponsored content April 3, 2024 In this interview, Ashley Tuan, OD, PhD, Chief Medical Officer of Visioneering Technologies Inc. (VTI) sat down...

1.0K

VTI’s Dr. Ashley Tuan Shares PROTECT Study’s One-Year Results

sponsored content March 4, 2024 In this video, Visioneering Technologies, Inc.’s Chief Medical Officer Dr. Ashley Tuan shares the one-year results of the...

933

VTI Shares Ongoing Results of One-Year PROTECT Trial

January 22, 2024 LAS VEGAS — Visioneering Technologies Inc. (VTI) is sharing results from its ongoing PROTECT Trial (PROgressive Myopia Treatment Evaluation...

713

Dr. Ashley Tuan Discusses VTI’s PROTECT Trial

sponsored content October 17, 2023 Review of Myopia Management’s Editor-in-Chief John Sailer interviewed Ashley Tuan, OD, PhD, Chief Medical Officer of Visioneering Technologies...

907

VTI Shares One-Year Data from PROTECT Trial at AAO 2023

October 12, 2023 NEW ORLEANS, La. — At the 2023 American Academy of Optometry meeting held here, Visioneering Technologies Inc. shared interim...

VTI’s NaturalVue Six-Year Data Confirmed by Three Independent Studies

September 8, 2023 CHICAGO — Visioneering Technologies Inc. completed a six-year clinical trial for its NaturalVue Multifocal (MF) contact lenses, and now,...

1.3K

VTI’s PROTECT Study Reaches 100% Enrollment

December 7, 2022 ATLANTA — Visioneering Technologies Inc.’s PROTECT (PROgressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial) study has officially reached 100% participant enrollment....

1.7K

Clinical

What Can Chicken Eyes Tell Us About Using NaturalVue Multifocals?

sponsored content August 1, 2022 By Ashley Tuan, OD, PhD, FAAO Randomized controlled chicken studies have shown relative myopic defocus from a...

VTI Reaches 50% Enrollment Milestone for PROTECT Study

July 13, 2022 ATLANTA – Medical device company and producer of NaturalVue Multifocal 1 Day Contact Lenses, Visioneering Technologies, Inc (ASX:VTI) announced...

VTI’s Six-Year Clinical Trial Data Published in Clinical Ophthalmology

July 8, 2022 ATLANTA — Findings from Visioneering Technologies Inc.’s (VTI) six-year myopia management clinical trial were published in the Clinical Ophthalmology journal. The study...

1.5K

Clinical

VTI’s CMO Dr. Ashley Tuan On NaturalVue and the PROTECT Study

sponsored content April 1, 2022 We believe that for myopia management, there needs to be a lot of tools in [the practitioner’s]...

2.3K